Abstract / Summary
Neuroinflammation is increasingly recognized as a determinant of dopaminergic neuron vulnerability in Parkinson's disease, yet the receptor-level mechanisms linking microglia to disease progression remain incompletely defined. We investigated whether microglial P2Y12 receptor (P2Y12R) signalling drives neurodegeneration in experimental Parkinsonism and assessed its pharmacological tractability. Tamoxifen-inducible microglia-specific P2ry12 deletion was examined in acute and subchronic MPTP models, with receptor deletion induced before or during disease progression. Neurodegeneration, neuroinflammation, neurochemistry, and motor function were evaluated, and novel P2Y12R antagonists identified by structure-based virtual screening were characterized in vitro and following central administration in vivo. Inducible microglia-specific P2Y12R deletion reduced nigrostriatal dopaminergic neuron loss, preserved dopamine synthesis, attenuated acute and sustained neuroinflammatory responses, and improved parkinsonian motor deficits without affecting survival. Importantly, delayed receptor deletion during ongoing neurodegeneration remained protective, indicating that P2Y12R contributes to disease progression. Two novel antagonists exhibited functional P2Y12R inhibition in vitro, and central administration of the most promising candidate recapitulated the neuroprotective phenotype observed following genetic receptor deletion. These findings identify microglial P2Y12R as a therapeutically relevant regulator of neuroinflammation and dopaminergic vulnerability and provide complementary genetic and pharmacological proof-of-concept for targeting central P2Y12R in Parkinsonism.